Certara (CERT) Projected to Post Quarterly Earnings on Monday

Certara (NASDAQ:CERT - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data after the market closes on Monday, May 5th. Analysts expect Certara to post earnings of $0.10 per share and revenue of $104.44 million for the quarter.

Certara Trading Down 2.3 %

Certara stock traded down $0.30 during trading hours on Friday, reaching $12.99. The stock had a trading volume of 2,963,026 shares, compared to its average volume of 1,247,217. Certara has a 52 week low of $8.64 and a 52 week high of $17.94. The stock has a market cap of $2.10 billion, a PE ratio of -64.95, a PEG ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a fifty day simple moving average of $11.68 and a 200-day simple moving average of $11.63.

Analysts Set New Price Targets

CERT has been the topic of several research reports. Barclays cut their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. KeyCorp lifted their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Finally, TD Cowen started coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $15.17.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.